519 results
SC TO-T/A
EX-99
Swedish Orphpan Biovitrum AB
26 Jun 23
Third party tender offer statement (amended)
9:20am
or results may differ from Sobi’s expectations due to risks and uncertainties inherent in Sobi’s business, including, without limitation: litigation
SC TO-T/A
Swedish Orphpan Biovitrum AB
9 Jun 23
Third party tender offer statement (amended)
4:02pm
after the last paragraph of such subsection with the caption “Litigation” and replacing it with the following paragraphs:
“On May 26, 2023, a purported
SC TO-T/A
Swedish Orphpan Biovitrum AB
2 Jun 23
Third party tender offer statement (amended)
7:01am
the following paragraphs immediately after the last paragraph of such subsection with the caption “Litigation:”
“On May 26, 2023, a purported CTI BioPharma
SC 14D9
CTIC
CTI BioPharma Corp
25 May 23
Tender offer solicitation
7:00am
, employees and stock price, as well as its ability to attract and retain key personnel while the transaction is pending.
Litigation Risk … . The execution of the Merger Agreement, the completion of the Offer and the consummation of the Merger increases the risk of litigation against CTI.
Interim
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
in connection with any litigation, arbitration or administrative proceedings or regulatory enquiry concerning the Acquisition);
(iv)
any Indemnified Person … of the Acquisition or the funding of the Acquisition (including but not limited to those incurred in connection with any litigation, arbitration
SC TO-T
EX-99
h4yolm59 k7
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
36pjdy432m
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
v7f31ee 9ivx3idmmmhe
25 May 23
Third party tender offer statement
6:46am
SC TO-C
EX-99.1
jo0d0xtl0b8asdh9j js
10 May 23
Information about tender offer
5:01pm
SC TO-C
EX-99.2
6yu95n6x1btojugkojio
10 May 23
Information about tender offer
5:01pm
SC14D9C
EX-99.1
2gi1fdcqxuzyj b08npx
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-2.1
bpa 0187jla8v50
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
EX-99.1
65jqx6hqqljrgu28jz
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-2.1
rosuvlbw03g9p9af
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-99.1
hj7a1
7 Nov 22
CTI BioPharma Reports Third Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
90e1 n6xkpaxocz6
28 Sep 22
Other Events
4:05pm